Project Grant R43CA309866
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10014, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Oncotab, Inc. $1,130,587 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct Phase II SBIR research on a bispecific antibody T-cell engager (muCD3) combined with chemotherapy for pancreatic cancer treatment. Oncotab will advance muCD3 through preclinical studies designed to de-risk its path toward first-in-human trials and commercialization. The work includes evaluating muCD3 structural...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Cancer Institute awarded Tezcat Biosciences, Inc., $399,855 on August 18, 2026, for tumor-targeted delivery of radio and chemotherapy in pancreatic cancer under the Cancer Treatment Research program (CFDA 93.395). Tezcat is developing a dual-payload drug candidate, TZT-102, that exploits macropinocytosis—a nutrient scavenging process overexpressed in mutant RAS pancreatic ductal adenocarcinoma cells—to deliver intracellular cytotoxic and radiotherapeutic agents. The compound...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $683,970 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor-penetrating stromal modification in pancreatic ductal adenocarcinoma through the αvβ5 integrin pathway. The research focuses on developing and evaluating the IRGD tumor-penetrating peptide as a therapeutic approach. The work examines how IRGD inhibits αvβ5-mediated transforming growth...
- The National Cancer Institute awarded the University of California, San Diego $411,206 on May 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small molecule inhibitors of the proton-sensing receptor GPR68 for pancreatic ductal adenocarcinoma therapy. The research targets the acidic tumor microenvironment in pancreatic cancer, which drives tumor progression and immunosuppression. The work will develop and test GPR68-targeting pharmacological agents designed to block...
- The National Cancer Institute awarded $400,000 to Dauntless Biotherapeutics, Inc. on August 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop CD155-targeted antibody-drug conjugates for metastatic and triple-negative breast cancer. The project advances therapeutic candidates that combine direct tumor cytotoxicity with restoration of anti-tumor immunity. CD155 is expressed in over 60% of breast cancers, including triple-negative, HER2-positive, and HER2-low...
- The National Cancer Institute awarded Virginia Commonwealth University $511,930 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify molecular determinants of response and resistance to TROP2-targeted antibody-drug conjugates and develop strategies to enhance therapeutic efficacy in triple-negative breast cancer and pancreatic adenocarcinoma. The project spans five years through July 31, 2031, with work performed in Richmond, Virginia. The research...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...
- The National Cancer Institute awarded $667,482 to the University of California, Davis on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop second-generation nanomedicine targeting treatment resistance in pancreatic ductal adenocarcinoma. The project develops an autophagy-inhibitor self-delivered nanodrug (AISN) containing a bisaminoquinoline derivative designed to overcome drug resistance driven by pancreatic cancer stem-like cells and drug-tolerant...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the Regents of the University of Minnesota $650,590 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate properties of T cell receptors that govern pancreatic cancer immunotherapy response. The funded research investigates how T cells function within the pancreatic tumor microenvironment and respond to immunotherapy, with a focus on T cell receptor (TCR) features...